One study recruited patients with melanoma who had failed PD-1/PD-L1 immunotherapy to pembrolizumab in combination with low-dose ipilimumab, with an ORR of 29%, a median survival time (MST) of 16.6 months, and a 3% rate of adverse events (29). Here, CD274 is linked to melanoma.